Spots Global Cancer Trial Database for peritoneal cavity cancer
Every month we try and update this database with for peritoneal cavity cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00112957 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | rV-NY-ESO-1 vac... rF-NY-ESO-1 vac... | 18 Years - | Ludwig Institute for Cancer Research | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01670799 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Ketorolac | 18 Years - | New Mexico Cancer Care Alliance | |
| Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | NCT00010179 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00825201 | Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | paclitaxel albu... liquid chromato... mass spectromet... pharmacological... laboratory biom... | 19 Years - | City of Hope Medical Center | |
| Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | NCT00287885 | Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... Sarcoma Vaginal Cancer Vulvar Cancer | docetaxel | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | NCT00004895 | Colorectal Canc... Constipation, I... Extrahepatic Bi... Gastric Cancer Gastrointestina... Nausea and Vomi... Ovarian Cancer Pancreatic Canc... Peritoneal Cavi... Small Intestine... | octreotide acet... | 18 Years - | Northwestern University | |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01670799 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Ketorolac | 18 Years - | New Mexico Cancer Care Alliance | |
| Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | NCT00245050 | Breast Cancer Drug/Agent Toxi... Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pyridoxine hydr... Placebo doxorubicin HCL... | - | Case Comprehensive Cancer Center | |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00217529 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pegfilgrastim carboplatin docetaxel erlotinib hydro... | 18 Years - | Fred Hutchinson Cancer Center | |
| S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer | NCT00043082 | Ovarian Cancer Peritoneal Cavi... | carboplatin pegylated lipos... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | NCT00003120 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | NCT00702299 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | cisplatin paclitaxel pemetrexed diso... biologic sample... | 18 Years - | University of Arizona | |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00382811 | Fallopian Tube ... Peritoneal Neop... Ovarian Cancer | phenoxodiol carboplatin placebo | 18 Years - | MEI Pharma, Inc. | |
| Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | NCT00030706 | Ovarian Cancer Peritoneal Cavi... | ixabepilone | 18 Years - 75 Years | Montefiore Medical Center | |
| Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00748527 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin decitabine | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | NCT00436644 | Ovarian Cancer Peritoneal Cavi... | Lapatinib Topotecan | 18 Years - | Mayo Clinic | |
| Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | NCT00436644 | Ovarian Cancer Peritoneal Cavi... | Lapatinib Topotecan | 18 Years - | Mayo Clinic | |
| Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer | NCT00003450 | Ovarian Cancer Peritoneal Cavi... | Ad5CMV-p53 gene | 18 Years - 120 Years | University of Texas Southwestern Medical Center | |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | NCT00008138 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel debulking surge... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | NCT00702299 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | cisplatin paclitaxel pemetrexed diso... biologic sample... | 18 Years - | University of Arizona | |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | NCT00293293 | Ovarian Cancer Peritoneal Prim... Fallopian Tube ... | healing touch massage therapy hypnosis Standard chemot... | - | Masonic Cancer Center, University of Minnesota | |
| Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT01137071 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Monoclonal anti... | 18 Years - | Recepta Biopharma | |
| PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | NCT00085384 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | PEG-interferon ... PEG-interferon ... PEG-interferon ... | - | M.D. Anderson Cancer Center | |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | NCT00466960 | Brenner Tumor Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Peritoneal Cavi... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | sargramostim paclitaxel albu... laboratory biom... immunologic tec... | 18 Years - | University of Washington | |
| Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies | NCT00625092 | Peritoneal Cavi... | fluorouracil leucovorin calc... oxaliplatin cytoreductive s... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT01137071 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Monoclonal anti... | 18 Years - | Recepta Biopharma | |
| Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | NCT00653328 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | atrasentan hydr... doxil | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00382811 | Fallopian Tube ... Peritoneal Neop... Ovarian Cancer | phenoxodiol carboplatin placebo | 18 Years - | MEI Pharma, Inc. | |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | NCT00354601 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | capecitabine docetaxel | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | NCT00101257 | Ovarian Cancer Peritoneal Cavi... | therapeutic aut... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | NCT00245050 | Breast Cancer Drug/Agent Toxi... Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pyridoxine hydr... Placebo doxorubicin HCL... | - | Case Comprehensive Cancer Center | |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | NCT00008138 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel debulking surge... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | NCT00004895 | Colorectal Canc... Constipation, I... Extrahepatic Bi... Gastric Cancer Gastrointestina... Nausea and Vomi... Ovarian Cancer Pancreatic Canc... Peritoneal Cavi... Small Intestine... | octreotide acet... | 18 Years - | Northwestern University | |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | NCT00354601 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | capecitabine docetaxel | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00003944 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim carboplatin cyclophosphamid... paclitaxel topotecan hydro... peripheral bloo... | 18 Years - | Fox Chase Cancer Center | |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | NCT01096381 | Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | laboratory biom... questionnaire a... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00331422 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel cytoreductive s... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00287859 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | topotecan hydro... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00825201 | Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | paclitaxel albu... liquid chromato... mass spectromet... pharmacological... laboratory biom... | 19 Years - | City of Hope Medical Center | |
| Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00030446 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin erlotinib hydro... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | NCT01096381 | Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | laboratory biom... questionnaire a... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00003944 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim carboplatin cyclophosphamid... paclitaxel topotecan hydro... peripheral bloo... | 18 Years - | Fox Chase Cancer Center | |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | NCT00357448 | Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Peritoneal Cavi... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | denileukin dift... intraperitoneal... laboratory biom... enzyme-linked i... flow cytometry | 18 Years - | University of Washington | |
| Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer | NCT00004081 | Ovarian Cancer Peritoneal Cavi... | docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | NCT00005049 | Colorectal Canc... Gastric Cancer Gastrointestina... Gastrointestina... Ovarian Cancer Peritoneal Cavi... Small Intestine... | carboplatin cisplatin floxuridine | 18 Years - | NYU Langone Health | |
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00112957 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | rV-NY-ESO-1 vac... rF-NY-ESO-1 vac... | 18 Years - | Ludwig Institute for Cancer Research | |
| Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | NCT00652899 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Allopurinol Cyclophosphamid... Fludarabine pho... total-body irra... Allogeneic natu... Aldesleukin | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00030446 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin erlotinib hydro... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00331422 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel cytoreductive s... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | NCT00369954 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin gemcitabine hyd... | 18 Years - | GOG Foundation | |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | NCT00293293 | Ovarian Cancer Peritoneal Prim... Fallopian Tube ... | healing touch massage therapy hypnosis Standard chemot... | - | Masonic Cancer Center, University of Minnesota | |
| Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00538031 | Fallopian Tube ... Peritoneal Cavi... Recurrent Ovari... | cyclophosphamid... celecoxib | 18 Years - | City of Hope Medical Center | |
| S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | NCT00003120 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | NCT00354601 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | capecitabine docetaxel | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer | NCT00652691 | Ovarian Cancer Peritoneal Cavi... | filgrastim carboplatin cyclophosphamid... topotecan hydro... autologous hema... peripheral bloo... | 18 Years - 70 Years | Mayo Clinic | |
| Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | NCT00010179 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | NCT00369954 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin gemcitabine hyd... | 18 Years - | GOG Foundation | |
| Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00903630 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Lenalidomide liposomal doxor... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 | NCT01074398 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | gene expression... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00825201 | Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | paclitaxel albu... liquid chromato... mass spectromet... pharmacological... laboratory biom... | 19 Years - | City of Hope Medical Center | |
| Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | NCT00030706 | Ovarian Cancer Peritoneal Cavi... | ixabepilone | 18 Years - 75 Years | Montefiore Medical Center | |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | NCT00008138 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel debulking surge... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer | NCT00004909 | Ovarian Cancer Malignant Tumor... Quality of Life | 18 Years - | Northwestern University | ||
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00217529 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pegfilgrastim carboplatin docetaxel erlotinib hydro... | 18 Years - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | NCT00005049 | Colorectal Canc... Gastric Cancer Gastrointestina... Gastrointestina... Ovarian Cancer Peritoneal Cavi... Small Intestine... | carboplatin cisplatin floxuridine | 18 Years - | NYU Langone Health | |
| Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00028743 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin cisplatin paclitaxel topotecan hydro... | 18 Years - 75 Years | Canadian Cancer Trials Group | |
| Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00897806 | Ovarian Cancer Peritoneal Cavi... | Microarray anal... Laboratory biom... | - | M.D. Anderson Cancer Center | |
| Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies | NCT00625092 | Peritoneal Cavi... | fluorouracil leucovorin calc... oxaliplatin cytoreductive s... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00897806 | Ovarian Cancer Peritoneal Cavi... | Microarray anal... Laboratory biom... | - | M.D. Anderson Cancer Center | |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | NCT01096381 | Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | laboratory biom... questionnaire a... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00028743 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin cisplatin paclitaxel topotecan hydro... | 18 Years - 75 Years | Canadian Cancer Trials Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
